Trobisch, Tim http://orcid.org/0000-0001-9317-8454
Zulji, Amel http://orcid.org/0000-0002-5185-1898
Stevens, Nikolas A.
Schwarz, Sophia
Wischnewski, Sven http://orcid.org/0000-0001-8714-1196
Öztürk, Mikail
Perales-Patón, Javier http://orcid.org/0000-0003-0780-6683
Haeussler, Maximilian
Saez-Rodriguez, Julio http://orcid.org/0000-0002-8552-8976
Velmeshev, Dmitry http://orcid.org/0000-0002-6491-7307
Schirmer, Lucas http://orcid.org/0000-0001-7142-4116
Funding for this research was provided by:
HORIZON EUROPE European Research Council (DecOmPress)
Medizinische Fakultät Mannheim der Universität Heidelberg
Article History
Received: 6 June 2022
Revised: 8 September 2022
Accepted: 8 September 2022
First Online: 16 September 2022
Declarations
:
: JSR receives funding from GSK and Sanofi and consultant fees from Travere Therapeutics and Astex Pharmaceuticals. LS filed a patent for the detection of antibodies against KIR4.1 in a subpopulation of patients with multiple sclerosis (WO2015166057A1).